STOCK TITAN
  1. Home
  2. Sec-filings
  3. TYRA
  4. [Form 4] Tyra Biosciences, Inc. Insider Trading Activity

TYRA Chief Operating Officer reports November insider stock sales

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Tyra Biosciences, Inc. reported insider stock sales by its Chief Operating Officer. The executive filed a Form 4 showing open-market sales of Tyra common stock on 11/18/2025 and 11/19/2025. On the first date, the officer sold 75,633 shares of common stock at a weighted average price of $16.0727, leaving 220,937 shares beneficially owned directly afterward. On the second date, the officer sold an additional 49,956 shares at a weighted average price of $16.3203, and reported direct beneficial ownership of 170,981 shares following that transaction. The filing notes that these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2024, which is designed to allow insiders to sell shares according to a preset schedule.

Positive

  • None.

Negative

  • None.
Insider Bensen Daniel
Role Chief Operating Officer
Sold 125,589 shs ($2.03M)
Type Security Shares Price Value
Sale Common Stock 49,956 $16.3203 $815K
Sale Common Stock 75,633 $16.0727 $1.22M
Holdings After Transaction: Common Stock — 170,981 shares (Direct)
Footnotes (1)
  1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.00 to $16.24. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.04 to $16.68. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bensen Daniel
(Last) (First) (Middle)
C/O TYRA BIOSCIENCES, INC.
2656 STATE STREET
(Street)
CARLSBAD CA 92008
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Tyra Biosciences, Inc. [ TYRA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Operating Officer
3. Date of Earliest Transaction (Month/Day/Year)
11/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/18/2025 S(1) 75,633 D $16.0727(2) 220,937 D
Common Stock 11/19/2025 S(1) 49,956 D $16.3203(3) 170,981 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.
2. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.00 to $16.24. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.04 to $16.68. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
/s/ Ali D. Fawaz, Attorney-in-Fact 11/19/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did TYRA disclose in this Form 4?

The Form 4 reports that Tyra Biosciences, Inc.'s Chief Operating Officer sold shares of common stock in open-market transactions on 11/18/2025 and 11/19/2025, and updated their remaining share ownership.

How many Tyra Biosciences (TYRA) shares did the COO sell on 11/18/2025?

On 11/18/2025, the Chief Operating Officer sold 75,633 shares of Tyra Biosciences common stock at a weighted average price of $16.0727 per share.

How many TYRA shares did the COO sell on 11/19/2025 and at what price?

On 11/19/2025, the Chief Operating Officer sold 49,956 shares of Tyra Biosciences common stock at a weighted average price of $16.3203 per share.

How many Tyra Biosciences (TYRA) shares does the COO own after these sales?

After the reported transactions, the Chief Operating Officer directly and beneficially owned 170,981 shares of Tyra Biosciences common stock.

Were the TYRA insider sales made under a Rule 10b5-1 trading plan?

Yes. The filing states that the sales were effected under a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024.

What price ranges applied to the TYRA stock sales disclosed?

For the 11/18/2025 sale, the filing states actual prices ranged from $16.00 to $16.24. For the 11/19/2025 sale, prices ranged from $16.04 to $16.68, with both days reported using weighted average sale prices.